Abstract:Combating influenza is one of the perennial global public health issues to be managed. Antiviral drugs are useful for the treatment of influenza in the absence of an appropriate vaccine. However, the appearance of resistant strains necessitates a constant search for new drugs. In this study, we investigated novel anti-influenza drug candidates using in vitro and in vivo assays. We identified anti-influenza hit compounds using a high-throughput screening method with a green fluorescent protein-tagged recombinant influenza virus. Through subsequent analyses of their cytotoxicity and pharmacokinetic properties, one candidate (IY7640) was selected for further evaluation. In a replication kinetics analysis, IY7640 showed greater inhibitory effects during the early phase of viral infection than the viral neuraminidase inhibitor oseltamivir. In addition, we observed that hemagglutinin (HA)-mediated membrane fusion was inhibited by IY7640 treatment, indicating that the HA stalk region, which is highly conserved across various (sub)types of influenza viruses, may be the molecular target of IY7640. In an escape mutant analysis in cells, amino acid mutations were identified at the HA stalk region of the 2009 pandemic H1N1 (pH1N1) virus. Even though the in vivo efficacy of IY7640 did not reach complete protection in a lethal challenge study in mice, these results suggest that IY7640 has potential to be developed as a new type of anti-influenza drug.IMPORTANCE Anti-influenza drugs with broad-spectrum efficacy against antigenically diverse influenza viruses can be highly useful when no vaccines are available. To develop new anti-influenza drugs, we screened a number of small molecules and identified a strong candidate, IY7640. When added at the time of or after influenza virus infection, IY7640 was observed to successfully inhibit or reduce viral replication in cells. We subsequently discovered that IY7640 targets the stalk region of the influenza HA protein, which exhibits a relatively high degree of amino acid sequence conservation across various (sub)types of influenza viruses. Furthermore, IY7640 was observed to block HA-mediated membrane fusion of H1N1, H3N2, and influenza B viruses in cells. Although it appears less effective against strains other than H1N1 subtype viruses in a challenge study in mice, we suggest that the small molecule IY7640 has potential to be optimized as a new anti-influenza drug.

Characterization of A Novel Fusion Inhibitor of Influenza A Virus

Characterization of Potent Fusion Inhibitors of Influenza Virus

Identification of a Novel Inhibitor Targeting Influenza A Virus Group 2 Hemagglutinins.

An Approach to the Identification of Potent Inhibitors of Influenza Virus Fusion Using Parallel Synthesis Methodology.

Identification of a Small-Molecule Inhibitor of Influenza Virus Via Disrupting the Subunits Interaction of the Viral Polymerase.

A Novel Small-Molecule Compound Disrupts Influenza A Virus PB2 Cap-Binding and Inhibits Viral Replication.

A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferon

A small-molecule fusion inhibitor of influenza virus is orally active in mice

Discovery and Characterization of a Novel Peptide Inhibitor Against Influenza Neuraminidase

Discovery of a Novel Specific Inhibitor Targeting Influenza A Virus Nucleoprotein with Pleiotropic Inhibitory Effects on Various Steps of the Viral Life Cycle

An N-terminal heptad repeat trimer-based peptide fusion inhibitor exhibits potent anti-H1N1 activity

Novel Small Molecule Targeting the Hemagglutinin Stalk of Influenza Viruses

Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus

A Broadly Protective Therapeutic Antibody Against Influenza B Virus with Two Mechanisms of Action

Identification of the Imidazo[1,2- a]pyrazine Derivative A4 as a Potential Influenza Virus Nucleoprotein Inhibitor

Identification of a novel compound targeting the nuclear export of influenza A virus nucleoprotein.

Design, Synthesis, and Biological Evaluation of Novel Penindolone Derivatives As Potential Inhibitors of Hemagglutinin-Mediated Membrane Fusion.

Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody

Computational Identification of a New Binding Site in Influenza Virus Hemagglutinin for Membrane Fusion Inhibitors

Single-chain Intracellular Antibodies Inhibit Influenza Virus Replication by Disrupting Interaction of Proteins Involved in Viral Replication and Transcription.

A pan-influenza antibody inhibiting neuraminidase via receptor mimicry